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Abstract
Introduction Integration of positron emission tomography
(PET) and magnetic resonance (MR) has become a topic of
increasing interest to the imaging community over the past
two years.
Objectives In this text, the authors attempt to distinguish
facts from fiction concerning such integrated systems.
Analysis of existing information of combined imaging on
existing brain PET/MR systems and imaging experience
with PET-computed tomography (CT) is reviewed. Various
types of system integration of PET and MR are discussed
with completely independent systems on one hand and
completely integrated systems with the possibility of simul-
taneous data acquisition on the other hand. Furthermore, it is
discussed, what simultaneous data acquisition with nuclear
imaging systems combined with MR or CT really means, as
technical simultaneity may not be relevant in light of the
pharmacokinetics of the nuclear tracers used.
Discussion The authors conclude that combining PET/MR
is an interesting research endeavor with uncertain outcome.
They argue that, while completely simultaneous brain
applications are of research interest immediately, clinical
applications do not currently warrant the construction of
fully integrated systems. Systems adjacent to each other,
where imaging tables are linked with a patient “shuttle”
thereby requiring only patient translation but no reposition-
ing, may be a good start to assess the value of integrated
PET/MR.
Keywords Integrated imaging . Dual modality imaging .
PET/CT.MRI
Introduction
Discussion on integration of positron emission tomography
(PET) and magnetic resonance (MR) has become fashion-
able in the last two years, and there is much speculation with
relatively few hard facts available. Combining PET and MRI
is an interesting undertaking with uncertain outcome: a true
research project encompassing basic science, technologic
and clinical questions. The aim of this paper is to summarize
existing knowledge on this topic and with a specific focus on
human applications.
Proof of concept of integrated imaging with single-
photon emission computed tomography (SPECT)-computed
tomography (CT) [1, 2] was provided in the late 1980s and
with PET/CT [3] in 1998. In both cases, the more
functional imaging methods of SPECT and PET are com-
bined with the more anatomical CT imaging information
within a single examination. With the advent of clinical
PET/CT in early 2001, it was quickly shown that integration
of PET and CT into a single system is advantageous and
synergistic, as it provides anatomic referencing and at the
same time permits transmission correction in a much shorter
time [4, 5], thus making PET/CT a more accurate [6] and
faster [7] imaging modality than PET alone, CT alone, and
even PET and CT read side-by-side [8–10]. Since its
clinical introduction in early 2001, it has become evident
that imaging with PET/CT will have an impact on
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therapeutic management in 20–50% of the examined
oncology cases [11]. Thus, this decade in imaging is clearly
the age of PET/CT and, to a lesser extent, SPECT-CT.
As MR has some advantages over CT, it is obvious to
evaluate, whether a combined PET/MR system may have
certain advantages over PET/CT. In order to design proper
PET/MR systems, it makes sense to use the experience of
PET/CT and try to look at the specifics of MR technology
interacting with PET technology and at their respective
clinical applications. The conjectures will be mostly clini-
cally oriented, as the authors are both clinicians and they
look to physicists, engineers, and the equipment manufac-
turers to provide technological solutions.
Facts
Image integration of two modalities like PET and MR or
PET and CT can be achieved in different ways as will be
analyzed in more detail in the next section. Essentially
integration can be achieved by software-based fusion or by
integration of the hardware of the two devices. Other issues
relevant to the ensuing discussion are:
1. MRI has become the clinical imaging modality of
choice in most neuro- and musculoskeletal applications.
2. MRI imaging from the head and neck to the pelvic
floor has its clinical role mainly in focal imaging of the
head and neck, the liver and other upper abdominal
organs as well as the pelvis.
3. Despite MR, CT has remained the method of choice in
staging patients from the head and neck to the pelvic floor
region; reasons include speed, robustness, and availabili-
ty of CT data acquisition and higher cost of MR.
4. CT has remained the method of choice in most cross-
sectional chest imaging.
5. MR offers functional imaging aspects not available
through CT.
6. Depending on how CT is used, it can contribute a sub-
stantial radiation burden to an integrated modality exam.
A low-dose CT scan in PET/CT yields a radiation expo-
sure of 2–3 mSv, while some CT protocols can yield
effective doses of up to 20 mSv [12]. This is mainly the
case in CT perfusion imaging because repetitive imaging
of the body region evaluated is needed to obtain the
bolus tracking data. FDG-PET imaging, for example,
causes effective dose levels on the order of 7–15 mSv,
depending on the injected dose.
What have we learned from PET/CT?
In clinical practice, we have learned several important things.
1. Inline PET/CT systems are quite adequate for most
body applications.
2. The most important clinical applications cover areas, in
which MR has not replaced CT, i.e., body oncology
applications, parts of infection imaging, and cardiac
imaging.
3. In areas, where MR excels clinically, i.e., neuro- and
musculoskeletal applications as well as some focal
body applications in the upper abdomen, pelvis, and
head and neck, both MR and PET/CT are frequently
performed both.
4. Comparison of separate PET/CT and MR data using
“mental” rather than software fusion is readily possible
because, with the CT of PET/CT, the PET data are
anatomically “framed”. Thus, there are enough ana-
tomic landmarks on both examinations, that computer
assisted image fusion is not necessary, when comparing
PET/CT with MR data.
5. Consecutive imaging on tightly coupled integrated
imaging systems may be inefficient from a workflow
perspective as either imaging system idles during parts
of the examination. Therefore, integrated imaging proce-
dures tend to be costly.
6. On the other hand, multimodality imaging performed
with separate imaging devices requires patient reposi-
tioning, which results in a greater risk of voluntary or
involuntary patient movements between procedures. If
images are misaligned, time-consuming side-by-side
image interpretation or software-based image fusion
may be required. Furthermore, patients need to be
positioned and repositioned twice rather than once
between scans, which is time consuming.
7. There are some physiologic processes such as tissue
perfusion, which may change so rapidly over time that
consecutive data acquisition of PET and MR data may
yield inaccurate results and fully integrated imaging is
necessary. However, this is of less importance for
current clinical applications.
Integrated PET/MR imaging: systems design issues
Recently, the feasibility of simultaneous PET/MR imaging
of the human head has been demonstrated by using a novel
avalanche photodiode-based PET detector technology,
which is insensitive even to high magnetic fields [13]. For
simultaneous PET/MR imaging of the human brain, a
detector ring was constructed, which fits in a standard
clinical 3-Tesla MRI scanner (TRIO, Siemens Medical
Solutions) and contains a standard bird cage transmit/
receive head coil [14]. All PET detector components
(amplifiers, resistors, shielding material, and housing) were
selected and dimensioned in order to exhibit minimal
interference with the static and gradient magnetic fields as
well as the radiofrequency irradiation of the MRI system.
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Initial human examinations have proven that the perfor-
mance neither of the PET nor the MRI scanner are
qualitatively compromised by each other compared to
separate systems [15]. Animal MR-PET systems have also
been described which allow quantitative assessment of
tracer uptake [16, 17]. With these experimental systems,
integrated PET/MR systems appear technically feasible. An
evaluation whether they might be of clinical or research use
is warranted. To better define the potential uses of a PET/
MR system, we have to first look at the various technical
options of how PET and MR can be integrated and second,
at some pharmacokinetic issues, relevant in PET imaging
with radiotracers.
First, there are three major ways to technically integrate
PET and MR systems:
A. Separate imaging in devices placed far from each
other. The patient has to get off one and onto the other
imaging system during the examination process. This
approach requires integration through software-based
image fusion and leaves full flexibility regarding the
placement of the two imaging systems and temporal
flexibility in the examination sequence of the patient.
The systems can also be used independently as single
imaging devices without interfering in their respective
operation.
B. Sequential imaging by systems which are linked by a
patient “shuttle”. The patient does not have to get off
the examination table of one device to get onto the
table of the second device as the transfer is accomplished
by the “shuttle”. Such devices provide “hardware-fused”
data. Sequential imaging designs (B) can be further
divided into 3 categories:
B1 Systems distant from each other, patients
shuttled, e.g., in restraining mattresses;
B2 Systems are in adjacent rooms and “shuttle”
links systems through a door;
B3 Systems in one room with patient “shuttle”
between both devices.
C. Fully integrated systems with technically simultaneous
data acquisition. Neither patient nor table motion is
required when imaging single fields of view
It is of note that all currently available PET/ and SPECT-CT
systems are of type B3. In these devices, the examination
table is the patient shuttle, and the distance between the
detection fields of view of the two imaging systems is in the
range of 50–100 cm. Similar solutions to B2 and B3 exist
in operating theaters where the operating room table is
linked to imaging devices such as MR scanners for
intraoperative imaging. The recently described experimen-
tal head PET/MR system is of type C [15]. In PET/CT and
SPECT-CT, such systems are also conceivable, but would
require development of detectors which can simultaneously
detect gamma rays and CT X-rays and discriminate
between them.
Second, we want to look at pharmacokinetics, as this
identifies whether and when simultaneity of imaging is
required. What does “simultaneous” really mean when
dealing with a combined PET/CT or PET/MR imaging
procedure. In Nuclear Medicine procedures, a radioactive
tracer is injected and—depending on its pharmacologic
properties—it distributes to the sites of interest. Hence,
pharmacokinetic behavior is critical, when we talk about
simultaneity. There are PET-tracers like O-15 water, which
enter and exit the volume of interest very quickly (within
minutes), while there are other tracers, such as ammonia
(N-13H3), which enter the cells quickly (also within a few
minutes) and then remain there in a pseudo-steady-state
(PSS) in proportion to local perfusion. Finally, there are
tracers, which build up in the structures of interest over an
extended period of time. In the case of fluorodeoxyglucose
(18F-FDG), a PSS distribution is reached after around
45 min and lasts for 30–60 min. Obviously, in a setting,
where no such PSS is reached, physically simultaneous
imaging may be relevant. However, when the distribution
of a radiopharmaceutical reaches a PSS, the imaging
protocol, i.e., the injection of radiotracer and possibly also
the MR contrast agent, as well as the subsequent imaging
steps in MR and PET have to be driven by considering
the pharmacokinetics of the tracer and contrast agents
used. For example, in a perfusion experiment of the heart
or brain with ammonia, it is important that the injection is
done while imaging the patient in the MR scanner because
the tracer distribution will reflect the state of perfusion at
the time of the MR examination. This is particularly
important, if a pharmacologic stress test, i.e., with
Dipyridamole or Adenosine is done. PET scanning can
be done later, as the perfusion state of the patient during
the “adenosine stress” MR scan was “frozen” by the
pharmacokinetic properties of the radiotracer ammonia.
With a study using FDG, the situation is yet different, and
the tracer may have to be injected even prior to the MR
scan. Once, the tracer distribution reaches a PSS, MR and
PET imaging can be acquired in sequence during the PSS
phase, or assuming that the patient state is not changing
during the initial uptake phase, MR can be done during
the FDG uptake phase assuming the patient state is not
changing.
With this insight, we can discuss options A, B, and C
defined above, and for this, refer to Table 1. The options
B1, B2, and B3 are considered separately. Note that the
sum total given in this table in the last row is of very
limited value as there is no way to attach appropriate
relative weights to the different categories. Furthermore, the
categories are not independent. Some comments are in
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order regarding the relative assessment of the five solutions
defined above:
1 Spatial data match: the shorter the time difference
between the data acquisitions on the two systems the
better the spatial match of the data. Here, full integration
is ideal. It is assumed that the patient “shuttling” times
between scanners in adjacent rooms are similar to those
between scanners within the same room. This makes
sense because, in one case, the distance between the
detection devices is 2–3 m, in the other, 5–8 m, which is
hardly relevant. Obviously, this is only true if shuttling
devices are efficient.
2 Technical simultaneity can only be achieved in systems
of type C, but transport times between systems are much
shorter, when they are adjacent (B2 and B3). Thus,
these options are advantageous compared to options A
and B1.
3 Pharmacological simultaneity sometimes mandates si-
multaneous data acquisition in PET and MR (thus five
points), but—in light of pharmacokinetics as discussed
above—in many current clinical applications, it is rather
contraindicated (thus two points). Therefore, in such
applications, flexibility in designing the proper proto-
cols driven by pharmacological considerations make
adjacent linked systems preferable.
4 Effective system use is a somewhat complex issue.
Separate systems have the advantage of full flexibility,
but the disadvantage, that for all patients, who get both
exams, placing and removing the patient from the
examination table occurs twice, and thus, patient
positioning in separate imaging requires twice as long
as for integrated imaging. The sum of these two times
per system is on the order of 15 min. During this time,
the systems are idling. If the imaging time in the single
device is less than this time, the changing time becomes
the rate-limiting step. For imaging times longer than the
times for re-/positioning and removing the patient, and
for imaging times, which are very different for each of
the integrated devices, independent systems are advan-
tageous. Thus, with typical effective imaging times for
PET of 15 min, CT of 5 min, and MR of 30 min or
more, PET/MR systems in independent rooms could
frequently be used more effectively than when in a
single room. The situation for PET/CT is different, as
particularly the CT examination is much faster. This is
not an in-depth analysis but rather states the relevant
issues, when considering workflow.
5 Ease of technical integration is related to the additional
engineering costs incurred for system integration. For
options A and B1 this is minimal (software and posi-
tioning devices); B2 requires a patient shuttle and B3 a
patient shuttle plus additional shielding measures of the
PET scanner from the main magnetic field of the MR
scanner. Option C requires complete re-engineering of
the detector systems for brain imaging and additional re-
engineering of the MR system. These measures are all
very costly, and personal experience of one of the
authors (GvS) with an interventional magnet with
central surgical access suggests that for magnet redesign
for a body system, development cost may be over EUR 7
M or € 7 M.
Table 1 Comparison of differ-
ent options (A–C) of integrat-
ing PET and MR using grades
from 0 to 5 (0 worst, 5 best)
PET/MR combination (A)
Separate
imaging
(B)
Sequential Imaging
(C)
Full
integration
Topic (B1)
Hardware
integration
distant
(B2)
Hardware
integration
adjacent rooms
(B3)
Hardware
integration
same room
Spatial data match 0 Brain: 1 4 4 5
Body: 2
Technical simultaneity 0 1 2 2 5
Pharmacologic simultaneity 1 2 4 4 5
Effective system use 4 3 3 1 2–4
Ease of tech. implementation 5 4 4 2 Brain: 1
Body: 0
Hardware compatibility 5 5 4 3 2
Same vendor Same vendor
System cost (high 0, low 5) 5 5 4 3 Brain: 2
Body: 0
Sum 20 Brain: 21 25 19 Brain: 22–24
Body: 22 Body: 19–21
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6 Hardware compatibility is again related to the degree of
integration. While options A and B1 do not require any
compatibility except for DICOM image format, B2, B3,
and, in particular, option C will likely have to be
provided by a single vendor, at least for a body-imaging
system. The overall assessment suggests that integrating
a system, where the two components are in adjacent but
independent rooms, is preferable when technical issues
and costs are taken into consideration. If engineering
funds are not an important restraint, then the fully
integrated system has its attractions, and research into
this option is highly desirable.
7 Overall system cost is directly related to points 5 and 6.
In summary, a deployment of a PET/MR system has to take
into account various technical, physiological, and design
aspects. While full integration even of body systems may
be the final goal, at this point, the fully integrated brain
imaging systems allow experience to be gained with this
new technology, while experience with non-neuro applica-
tions of PET/MR body imaging (but even including some
brain applications) may be gained with systems integrated
to a lesser degree. Table 1 suggests that the preferred design
for body applications is a “shuttle” linked PET/MR scanner
consisting of two independent scanners in adjacent rooms,
as it combines the advantage of a closely linked system
with maximum flexibility of use.
Integrated PET/MR: attenuation correction
Variable photon attenuation in tissue is a cause of image
degradation in all Nuclear Medicine emission imaging
procedures including PET. Accordingly, measurement of
the spatial distribution of attenuation is a prerequisite to
reconstruct PET images rendering true tracer distributions,
thereby permitting semiquantitative evaluation of images
by measuring standard uptake values (SUV). In PET/MR
systems, two potential sources of photon attenuation have
to be considered:
(1) PET photon attenuation caused by the MR gradient
and RF coils with their electronic components: This
problem can be solved by acquiring a CT image of the
head coil once and integrating the data into the image
reconstruction algorithm. The problem only occurs in
option C with fixed coils, but may be a problem with
surface coils in all types of integrated systems, since
removing of surface coils likely requires patient re-
positioning, which is undesirable.
(2) Attenuation correction is a caused by patient tissue is
relatively straightforward in PET/CT examinations, as
non-enhanced whole-body CT scans are an integral
part of the examination. CT scans (around 100 kVp
data) can be easily converted into an attenuation mu-
map at 511 kVp for PET using a bilinear function [5],
which can then be incorporated into the reconstruction
algorithm for PET thereby correcting for patient
attenuation. MRI, on the other hand, yields no
information about photon attenuation but rather tissue
proton densities and magnetic relaxation times. Par-
ticularly, bone and air appear with similar low signal
intensity on MR images despite having the highest and
lowest photon attenuation coefficients, respectively.
Attenuation correction of PET/MR must therefore be
based on an indirect voxel-by-voxel assignment of
MR signal intensities to empirical values of photon
attenuation coefficients [18]. Alternative methodologi-
cal approaches are currently under development for
calculating so called “pseudo-CT images”. One ap-
proach uses image segmentation [19]; another a
combination of local pattern recognition with atlas
registration for additionally capturing global variations
of anatomy [20]. The latter approach has been shown
to be successful for brain MR/PET images by suc-
cessfully calculating artefact-free images and quanti-
tative SUV values. However, the brain is a relatively
homogeneous structure and using the same procedure
in body PET/MR may be more difficult. Despite these
initial successes, an integrated PET/MR for body
imaging would probably be based on sequential partly
integrated PET/CT and an MR systems for the time
being.
Advantages of PET/CT and PET/MR
PET enables quantitative and semiquantitative evaluation of
tracer uptake kinetics of any small molecule which can be
labeled with standard positron emitters. Clinically, by far,
the most frequently used radiopharmaceutical is FDG, and
FDG-PET/CT has been proven to be an important tool for
diagnosis, staging, and therapy monitoring. CT is a fast and
standardized method which performs well even in uncoop-
erative patients, reliably yielding highly standardized image
data even in examinations repeated on different days [21].
In recent years, PET/CT has established itself as an imaging
method that works robustly in clinical routine. Long-
standing clinical experience exists for both modalities
PET and CT. In a PET/CT examination, PET and CT are
performed in rapid sequence, and as CT is very fast and
also provides the data for PET attenuation correction, a
PET/CT examination is typically 25–30% less time con-
suming than the acquisition of an attenuation-corrected PET
scan.
PET/MR on the other hand is still in its early stages of
development and several technological and methodical
issues have to be addressed before PET/MR can establish
itself as a clinical routine tool. As discussed, the technical
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issues are related to the incompatibility of current MR and
PET systems mandating new developments in MR and PET
systems mandating technology as well as related to the
currently unresolved issue of PET attenuation correction
with MR image data. The latter is critical particularly for
therapy monitoring. Consequently, fully integrated PET/
MR at the present stage of development basically represents
a research tool and so far is only available as a dedicated
brain scanner.
From a scientific and clinical point of view, a fully
integrated PET/MR may have some advantages over PET/
CT:
1. The superior soft tissue contrast of MRI allows better
anatomical visualization of soft tissue structures and
bone marrow than CT.
2. Simultaneous image acquisition enables temporal co-
registration of dynamic PET data acquisition and
morphologic/functional MR data. A variety of func-
tional information can be acquired by MR, e.g.,
perfusion (microvessel density, vessel leakage, etc.),
diffusion (cell density, microstructure, etc.), and me-
tabolism (cell death, proliferation, etc.). Moreover,
brain activation can be studied by functional MRI
(fMRI). A vast array of applications mostly relevant in
research can be conceived with such a system [14, 15],
but even PET/MR systems of type B2 and B3 will be
quite useful in view of the discussion on the relevance
of tracer pharmacokinetics given above.
3. Some studies comparing whole-body MR with PET/CT
have shown potential advantages of MR particularly
regarding the early detection of brain-, liver- and bone
marrow metastases [22–24]. If these data are con-
firmed, PET/MR can be assumed to have an advantage
over PET/CT in some oncology applications. To benefit
from these potential advantages, full PET/MR system
integration is not required.
4. In fully integrated systems, MRI could also be used to
provide a gating signal in addition to imaging. This is
however only advantageous, when MR data acquisi-
tion, MR gating data, and PET data are acquired
simultaneously and for similar amounts of time, as
otherwise MR is just an expensive device to provide
gating information for PET.
5. MR does not expose the patient to ionizing radiation.
Thus, replacing CT by MR in such an integrated system
is expected to result in radiation dose reductions
depending on the imaging protocol. This is mainly
relevant in pediatric applications.
6. Fully integrated PET and MR imaging reduces the scan
time for the patient compared to sequential scanning.
Summarizing and hypothesizing on the limited data
available, PET/MR in its various deployment options will
be a valuable tool, which in some applications is likely to
be superior to PET/CT. Clinically, these will be most likely
in brain- and musculoskeletal imaging. However, in the
brain, current clinical applications will be equally as
effective using software rather than hardware image
integration. In musculoskeletal imaging, PET/MR may be
of major clinical interest, as MR is excellent and PET has
two routine tracers available for musculoskeletal imaging,
which have been shown to provide clinically relevant data:
FDG and 18F-flouride for PET-bone imaging. Integrated
PET/MR for brain imaging is likely to be a formidable
research tool for the foreseeable time.
Expertise and training:
As an increasing number of PET/CT and in the future
possibly also PET/MR scanners are installed, there will
accordingly be an increasing demand for imaging special-
ists in reading the imaging data from such combined
systems. Appropriate training in Radiology and Nuclear
Medicine is a prerequisite for successful clinical interpre-
tation and also for performing research on these systems.
The most effective way of reading the images is by doubly
board certified experts, but currently, in many sites, a
nuclear physician and a radiologist read the images
separately with ensuing discussion of the results. It is not
acceptable to read CT or MR only for anatomic correlation
of PET findings, as important findings can be missed,
which have to be an integral part of the diagnosis. Efforts
by the US and European [25] societies are under way for
optimized training, and there are also fellowship training
programs available, which enable the relevant expertise to
be obtained [http://www.nuk.usz.ch/german/LehreUndFor-
schung/Fellowship+Program/TrainingProgram/].
Conclusions
At the current stage of technological development, PET/MR
systems based on two imaging systems in close proximity
and connected by some kind of a patient shuttle together
with software tools for image integration including methods
for MR-based attenuation correction appear optimal for
evaluating the clinical value of whole-body PET/MR.
Likely, the PET part of such systems is actually a PET/
CT, which solves the yet unresolved PET attenuation
correction issues with MR data. Fully integrated systems
have several scientific and possibly also clinical advan-
tages. Two types of integrated PET/MR for head imaging
research studies are already in use. Fully integrated whole-
body PET/MR systems will however need considerable
more technological and methodological analysis and devel-
opment before it can be decided whether such systems are
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useful in settings beyond those of research-oriented
academic centers. Prime clinical applications for PET/MR
systems are likely in the brain and the musculoskeletal
system, but interesting applications in other body areas can
also be envisioned.
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